Gilead Sciences, Inc. vs LTC Properties Inc — how do they compare? Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B), while LTC Properties Inc trades at $38.12 (market cap $2.05B). The key difference: Gilead Sciences, Inc. is far larger — about 82.1× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.98%). Which is the better fit depends on your goals.
| GILD | LTC | |
|---|---|---|
Market Cap | $168.35B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $42.81 |
52-Week Low | $110.56 | $33.98 |
Enterprise Value | $191.42B | $2.79B |
Dividend Yield | 2.42% | 5.98% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →